VO (RP1)

· Replimune, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for VO (RP1), covering 2025-12-18 to 2025-12-18. Get the full timeline:

Most recent: Clinical Trial Update: An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced Melanoma